ACCPL (ACCPL) fundamentals
ACCPL is a listed company, part of the Pharmaceuticals sector, listed on the NSE as ACCPL (ISIN INE0T8T01010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What ACCPL does
Accretion Pharmaceuticals Limited is an India-based company. The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kinds of drugs, pharmaceutical products and related products. Its product portfolio includes five verticals, such as tablet, oral liquid, external preparation, capsule, and oral powder. Its products include Azithromycin 250 mg/500 mg, Ciprofloxacin 250/500 mg, Ketoconazole 200 mg, Levofloxacin 250mg/500 mg, Levofloxacin 250 mg+Ornidazole 500 mg, Itraconazole 100mg/200 mg (AS PELLETS), Ofloxacin 100mg + Metronidazole 200mg suspension, Aceclofenac 100mg+Paracetamol 325 mg, Deflazacort 6 mg, Ibuprofen 400mg/600mg, Mefenamic acid 250mg+Dicyclomine HCL 10mg, Nimesulide MD 100mg, Doxofylline 400 mg, Ibuprofen 100mg oral suspension, Montelukast 5mg/10mg, Cetirizine dihydrochloride 5mg/10mg, Omeprazole 20mg, Ondansetron 2 mg Syrup, and others.
Valuation and market data
| Last close | ₹215.00 |
|---|---|
| Market capitalisation | ₹172 crore |
| Enterprise value | ₹173 crore |
| P/E (TTM) | 0.00 |
| Price to book | 11.26 |
| Price to sales (TTM) | 0.00 |
| Book value per share | ₹19.10 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹90 crore | ₹13 crore | ₹10 crore | 0.00 |
| Mar 2025 | ₹57 crore | ₹10 crore | ₹7 crore | 8.48 |
| Mar 2024 | ₹13 crore | ₹2 crore | ₹1 crore | 1.96 |
| Mar 2023 | ₹30 crore | ₹0 crore | ₹0 crore | 0.00 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 73.5% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 2.8% |
| Retail and others | 23.7% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.